PofoliaShared via Pofolia

Circulation Heart Failure· 2026Q1

Get With The Guidelines–Heart Failure Hospital Participation and Its Association With Guideline-Directed Medical Therapy and Outcomes

Aradhana Verma, G Fonarow, Paul Heidenreich, Larry A Allen et al.

Short summary

Hospitals participating in the Get With The Guidelines–Heart Failure (GWTG-HF) program showed a 0.15-point higher 90-day GDMT score and a significant reduction in all-cause mortality at 30 days, 90 days, and 1 year compared to non-participating hospitals.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Hospitals participating in GWTG-HF showed a 0.15-point higher 90-day GDMT score compared to non-participating hospitals.
  • GWTG-HF participation was associated with greater use of beta blockers, RASIs, and MRAs.
  • All-cause mortality was significantly lower at 30 days (OR 0.95), 90 days (OR 0.97), and 1 year (0.97) in GWTG-HF participating hospitals.
  • No significant difference was observed in HF readmission rates between participating and non-participating hospitals.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract Purpose Despite strong evidence, real-world adoption of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal. The Get With The Guidelines–Heart Failure (GWTG-HF) program was designed to close gaps in care. We evaluated whether hospital participation in GWTG-HF is associated with greater GDMT intensity and improved outcomes. Methods We conducted a retrospective analysis (2013-2021) of Medicare beneficiaries with Part A and Part D hospitalized with HFrEF. Using a multiple baseline time series design, we compared changes in GDMT prescribing and outcomes at hospitals before and after GWTG-HF enrollment with hospitals that never participated. The primary outcome was a 90-day post-discharge prescription-fill GDMT score summarizing use and dose of beta blockers, renin-angiotensin system inhibitors (RASI; ACE inhibitor/ARB/ARNI), and mineralocorticoid receptor antagonists (MRA). Secondary outcomes included class-specific medication fills, achievement of ≥50% target doses, and 30-day, 90-day, and 1-year all-cause and HF readmission and mortality. We adjusted for baseline hospital performance, patient characteristics, and temporal trends. Results Among 1,274,863 Medicare beneficiaries hospitalized for HFrEF, 53.5% were treated at hospitals that never participated in GWTG-HF and 9.6% at hospitals that joined GWTG-HF before hospitalization. Unadjusted median GDMT scores increased from 3.0 in both groups to 4.0 in non-participating hospitals and 4.5 in GWTG-HF hospitals at 90 days (p<0.001). Hospital enrollment was associated with a higher 90-day GDMT score (+0.15 points; 95% CI 0.12-0.18; p<0.001), and greater use of beta blockers, RASI, and MRA, but not ARNI. HF readmission did not differ significantly; however, GWTG-HF participation was associated with lower all-cause mortality at 30 days (OR 0.95; 95% CI:0.92-0.98), 90 days (OR: 0.97; 95% CI: 0.95-0.99), and 1 year (0.97; 95% CI: 0.95-.0.99; all p<0.05). Conclusion Hospital participation in GWTG-HF was associated with higher GDMT intensity and lower mortality, supporting structured quality programs to improve HFrEF care.

The authors' abstract, as published at the source. Circulation Heart Failure, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Cardiology and Cardiovascular Medicine

Cardiology and Cardiovascular MedicineMedicine